Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

We recently reported promising clinical activity for a 10-day regimen of decitabine in older AML patients; high miR-29b expression associated with clinical response. Subsequent preclinical studies with bortezomib in AML cells have shown drug-induced miR-29b up-regulation, resulting in loss of transc...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Blum, William, Schwind, Sebastian, Tarighat, Somayeh S., Geyer, Susan, Eisfeld, Ann-Kathrin, Whitman, Susan, Walker, Alison, Klisovic, Rebecca, Byrd, John C., Santhanam, Ramasamy, Wang, Hongyan, Curfman, John P., Devine, Steven M., Jacob, Samson, Garr, Celia, Kefauver, Cheryl, Perrotti, Danilo, Chan, Kenneth K., Bloomfield, Clara D., Caligiuri, Michael A., Grever, Michael R., Garzon, Ramiro, Marcucci, Guido
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2012
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3383015/
https://ncbi.nlm.nih.gov/pubmed/22566605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-03-413898
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg